A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC
Abroad (travel likely)RecruitingPHASE2
Conditions
Hepatocellular Carcinoma (HCC)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
the Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China